Table 2.
The HSD17B13 rs72613567 and rs6834314 allele frequencies and association tests in biopsy-proven NAFLD patients compared with controls
| Allele frequency | OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | |
|---|---|---|---|---|---|
| rs72613567 TA allele | |||||
| NAFLD vs. control | |||||
| Overall | 0.24 vs. 0.34 | 0.58 (0.40–0.86) | 0.006 | 0.59 (0.40–0.88) | 0.009 |
| Malays | 0.28 vs. 0.40 | 0.60 (0.33–1.09) | 0.092 | 0.62 (0.34–1.13) | 0.117 |
| Chinese | 0.26 vs. 0.41 | 0.41 (0.21–0.81) | 0.010 | 0.31 (0.15–0.67) | 0.003 |
| Indians | 0.11 vs. 0.14 | 0.78 (0.31–1.97) | 0.597 | 0.71 (0.27–1.87) | 0.492 |
| NAFL vs. control | |||||
| Overall | 0.27 vs. 0.34 | 0.73 (0.39–1.37) | 0.330 | 0.72 (0.38–1.38) | 0.326 |
| Malays | 0.22 vs. 0.40 | 0.45 (0.18–1.11) | 0.081 | 0.49 (0.20–1.24) | 0.132 |
| Chinese | 0.50 vs. 0.41 | 1.98 (0.51–7.71) | 0.327 | 1.81 (0.44–7.53) | 0.414 |
| Indians | 0.06 vs. 0.14 | 0.39 (0.04–3.44) | 0.392 | 0.30 (0.03–2.98) | 0.303 |
| NASH vs. control | |||||
| Overall | 0.23 vs. 0.34 | 0.55 (0.36–0.83) | 0.004 | 0.55 (0.36–0.83) | 0.005 |
| Malays | 0.31 vs. 0.40 | 0.65 (0.35–1.23) | 0.187 | 0.67 (0.35–1.28) | 0.224 |
| Chinese | 0.20 vs. 0.41 | 0.27 (0.13–0.57) | 0.001 | 0.19 (0.08–0.45) | <0.001 |
| Indians | 0.12 vs. 0.14 | 0.87 (0.33–2.26) | 0.772 | 0.83 (0.31–2.24) | 0.708 |
| NASH vs. NAFL | |||||
| Overall | 0.23 vs. 0.27 | 0.75 (0.39–1.43) | 0.384 | 0.75 (0.39–1.44) | 0.386 |
| Malays | 0.31 vs. 0.22 | 1.46 (0.61–3.49) | 0.402 | 1.51 (0.62–3.67) | 0.368 |
| Chinese | 0.20 vs. 0.50 | 0.14 (0.03–0.57) | 0.006 | 0.13 (0.03–0.57) | 0.007 |
| Indians | 0.12 vs. 0.06 | 2.26 (0.25–20.65) | 0.471 | 2.25 (0.23–22.13) | 0.488 |
| rs6834314 G allele | |||||
| NAFLD vs. control | |||||
| Overall | 0.26 vs. 0.39 | 0.59 (0.40–0.86) | 0.006 | 0.59 (0.40–0.87) | 0.009 |
| Malays | 0.31 vs. 0.44 | 0.65 (0.36–1.20) | 0.171 | 0.66 (0.36–1.22) | 0.189 |
| Chinese | 0.29 vs. 0.45 | 0.39 (0.20–0.77) | 0.006 | 0.31 (0.14–0.66) | 0.002 |
| Indians | 0.12 vs. 0.19 | 0.71 (0.29–1.74) | 0.458 | 0.64 (0.25–1.64) | 0.355 |
| NAFL vs. control | |||||
| Overall | 0.29 vs. 0.39 | 0.79 (0.42–1.48) | 0.453 | 0.74 (0.38–1.47) | 0.391 |
| Malays | 0.26 vs. 0.44 | 0.54 (0.22–1.31) | 0.173 | 0.60 (0.24–1.49) | 0.267 |
| Chinese | 0.50 vs. 0.45 | 2.52 (0.52–12.15) | 0.250 | 2.26 (0.44–11.61) | 0.329 |
| Indians | 0.06 vs. 0.19 | 0.31 (0.04–2.79) | 0.299 | 0.20 (0.02–1.90) | 0.160 |
| NASH vs. control | |||||
| Overall | 0.26 vs. 0.39 | 0.54 (0.36–0.82) | 0.003 | 0.48 (0.31–0.75) | 0.001 |
| Malays | 0.33 vs. 0.44 | 0.70 (0.37–1.32) | 0.270 | 0.71 (0.37–1.35) | 0.291 |
| Chinese | 0.23 vs. 0.45 | 0.25 (0.12–0.53) | <0.001 | 0.20 (0.09–0.45) | <0.001 |
| Indians | 0.13 vs. 0.19 | 0.81 (0.32–2.03) | 0.648 | 0.76 (0.29–2.00) | 0.582 |
| NASH vs. NAFL | |||||
| Overall | 0.26 vs. 0.29 | 0.69 (0.36–1.31) | 0.256 | 0.69 (0.36–1.32) | 0.263 |
| Malays | 0.33 vs. 0.26 | 1.30 (0.55–3.09) | 0.555 | 1.37 (0.57–3.30) | 0.485 |
| Chinese | 0.23 vs. 0.50 | 0.10 (0.02–0.50) | 0.005 | 0.10 (0.02–0.50) | 0.006 |
| Indians | 0.13 vs. 0.06 | 2.57 (0.28–23.31) | 0.402 | 2.29 (0.23–22.48) | 0.476 |
NAFL was defined as hepatic steatosis with no or only mild lobular inflammation and no hepatocyte ballooning. NASH was defined as the presence of hepatic steatosis, lobular inflammation and hepatocyte ballooning (at least grade 1 each) with or without fibrosis.
Logistic regression was used to obtain OR. The adjusted OR was adjusted for age and gender.
Control was the reference group in analysis NAFLD vs. control, NAFL vs. control and NASH vs. control. NAFL was used as the reference group in analysis for NASH vs. NAFL.
HSD17B13, 17β-hydroxysteroid dehydrogenase 13; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; CI, confidence interval; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis.